Epoetin Alfa
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy (NCT00306267) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-03-01 |
Track Epoetin Alfa automatically
Every clearance here is in the API, with alerts when new ones post.